Matches in SemOpenAlex for { <https://semopenalex.org/work/W2059404773> ?p ?o ?g. }
- W2059404773 abstract "Background Peripheral arterial occlusive disease (PAOD) is a common cause of morbidity and mortality due to cardiovascular disease in the general population. Although numerous treatments have been adopted for patients at different disease stages, no option other than amputation is available for patients presenting with critical limb ischaemia (CLI) unsuitable for rescue or reconstructive intervention. In this regard, prostanoids have been proposed as a therapeutic alternative, with the aim of increasing blood supply to the limb with occluded arteries through their vasodilatory, antithrombotic, and anti‐inflammatory effects. This is an update of a review first published in 2010. Objectives To determine the effectiveness and safety of prostanoids in patients with CLI unsuitable for rescue or reconstructive intervention. Search methods For this update, the Cochrane Vascular Information Specialist searched the Specialised Register (January 2017) and the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 1). In addition, we searched trials registries (January 2017) and contacted pharmaceutical manufacturers, in our efforts to identify unpublished data and ongoing trials. Selection criteria Randomised controlled trials describing the efficacy and safety of prostanoids compared with placebo or other pharmacological control treatments for patients presenting with CLI without chance of rescue or reconstructive intervention. Data collection and analysis Two review authors independently selected trials, assessed trials for eligibility and methodological quality, and extracted data. We resolved disagreements by consensus or by consultation with a third review author. Main results For this update, 15 additional studies fulfilled selection criteria. We included in this review 33 randomised controlled trials with 4477 participants; 21 compared different prostanoids versus placebo, seven compared prostanoids versus other agents, and five conducted head‐to‐head comparisons using two different prostanoids. We found low‐quality evidence that suggests no clear difference in the incidence of cardiovascular mortality between patients receiving prostanoids and those given placebo (risk ratio (RR) 0.81, 95% confidence interval (CI) 0.41 to 1.58). We found high‐quality evidence showing that prostanoids have no effect on the incidence of total amputations when compared with placebo (RR 0.97, 95% CI 0.86 to 1.09). Adverse events were more frequent with prostanoids than with placebo (RR 2.11, 95% CI 1.79 to 2.50; moderate‐quality evidence). The most commonly reported adverse events were headache, nausea, vomiting, diarrhoea, flushing, and hypotension. We found moderate‐quality evidence showing that prostanoids reduced rest‐pain (RR 1.30, 95% CI 1.06 to 1.59) and promoted ulcer healing (RR 1.24, 95% CI 1.04 to 1.48) when compared with placebo, although these small beneficial effects were diluted when we performed a sensitivity analysis that excluded studies at high risk of bias. Additionally, we found evidence of low to very low quality suggesting the effects of prostanoids versus other active agents or versus other prostanoids because studies conducting these comparisons were few and we judged them to be at high risk of bias. None of the included studies assessed quality of life. Authors' conclusions We found high‐quality evidence showing that prostanoids have no effect on the incidence of total amputations when compared against placebo. Moderate‐quality evidence showed small beneficial effects of prostanoids for rest‐pain relief and ulcer healing when compared with placebo. Additionally, moderate‐quality evidence showed a greater incidence of adverse effects with the use of prostanoids, and low‐quality evidence suggests that prostanoids have no effect on cardiovascular mortality when compared with placebo. None of the included studies reported quality of life measurements. The balance between benefits and harms associated with use of prostanoids in patients with critical limb ischaemia with no chance of reconstructive intervention is uncertain; therefore careful assessment of therapeutic alternatives should be considered. Main reasons for downgrading the quality of evidence were high risk of attrition bias and imprecision of effect estimates." @default.
- W2059404773 created "2016-06-24" @default.
- W2059404773 creator A5010356284 @default.
- W2059404773 creator A5029397330 @default.
- W2059404773 creator A5046109467 @default.
- W2059404773 creator A5047859296 @default.
- W2059404773 creator A5052739455 @default.
- W2059404773 creator A5081300556 @default.
- W2059404773 date "2018-01-10" @default.
- W2059404773 modified "2023-10-16" @default.
- W2059404773 title "Prostanoids for critical limb ischaemia" @default.
- W2059404773 cites W1502536193 @default.
- W2059404773 cites W1559845771 @default.
- W2059404773 cites W1564651773 @default.
- W2059404773 cites W1692295083 @default.
- W2059404773 cites W1692363465 @default.
- W2059404773 cites W1816543237 @default.
- W2059404773 cites W183210550 @default.
- W2059404773 cites W1839386982 @default.
- W2059404773 cites W1841673705 @default.
- W2059404773 cites W1854426312 @default.
- W2059404773 cites W1928960544 @default.
- W2059404773 cites W1948704512 @default.
- W2059404773 cites W1964417908 @default.
- W2059404773 cites W1968684647 @default.
- W2059404773 cites W1990131427 @default.
- W2059404773 cites W1992400770 @default.
- W2059404773 cites W1999240677 @default.
- W2059404773 cites W2012570517 @default.
- W2059404773 cites W2014179250 @default.
- W2059404773 cites W2028754364 @default.
- W2059404773 cites W2036690653 @default.
- W2059404773 cites W2044050313 @default.
- W2059404773 cites W2046841614 @default.
- W2059404773 cites W2047784954 @default.
- W2059404773 cites W204863220 @default.
- W2059404773 cites W2059404773 @default.
- W2059404773 cites W2060215549 @default.
- W2059404773 cites W2062939365 @default.
- W2059404773 cites W2066428911 @default.
- W2059404773 cites W2067391817 @default.
- W2059404773 cites W2075061346 @default.
- W2059404773 cites W2078829390 @default.
- W2059404773 cites W207898044 @default.
- W2059404773 cites W2088734405 @default.
- W2059404773 cites W2104675861 @default.
- W2059404773 cites W2120863449 @default.
- W2059404773 cites W2134236426 @default.
- W2059404773 cites W2139823928 @default.
- W2059404773 cites W2141848606 @default.
- W2059404773 cites W2144534193 @default.
- W2059404773 cites W2144985796 @default.
- W2059404773 cites W2148374679 @default.
- W2059404773 cites W2152643830 @default.
- W2059404773 cites W2156787895 @default.
- W2059404773 cites W2157885004 @default.
- W2059404773 cites W2158207432 @default.
- W2059404773 cites W2163675786 @default.
- W2059404773 cites W2166263011 @default.
- W2059404773 cites W2169365440 @default.
- W2059404773 cites W2222741751 @default.
- W2059404773 cites W2275759976 @default.
- W2059404773 cites W2279728460 @default.
- W2059404773 cites W2342634071 @default.
- W2059404773 cites W2397771943 @default.
- W2059404773 cites W2400352279 @default.
- W2059404773 cites W2401374501 @default.
- W2059404773 cites W2405185479 @default.
- W2059404773 cites W2406763298 @default.
- W2059404773 cites W2409153978 @default.
- W2059404773 cites W2410011265 @default.
- W2059404773 cites W2410995505 @default.
- W2059404773 cites W2412901990 @default.
- W2059404773 cites W2415334207 @default.
- W2059404773 cites W2423059573 @default.
- W2059404773 cites W2426329343 @default.
- W2059404773 cites W2427700735 @default.
- W2059404773 cites W2430529193 @default.
- W2059404773 cites W2461030538 @default.
- W2059404773 cites W2465853107 @default.
- W2059404773 cites W2466204160 @default.
- W2059404773 cites W2506628118 @default.
- W2059404773 cites W2556838984 @default.
- W2059404773 cites W2588681363 @default.
- W2059404773 cites W2887712073 @default.
- W2059404773 cites W2916841405 @default.
- W2059404773 cites W31374955 @default.
- W2059404773 cites W3158144670 @default.
- W2059404773 cites W36562551 @default.
- W2059404773 cites W4230082545 @default.
- W2059404773 cites W4233746681 @default.
- W2059404773 cites W4236544871 @default.
- W2059404773 cites W4236938366 @default.
- W2059404773 cites W4238072459 @default.
- W2059404773 cites W4240123733 @default.
- W2059404773 cites W4243204328 @default.
- W2059404773 cites W4249879042 @default.
- W2059404773 cites W4251088628 @default.
- W2059404773 cites W4251200865 @default.
- W2059404773 cites W4302467251 @default.